Calcium alpha-ketoglutarate shows opposing lung-tumor effects in female and male mice

Calcium alpha-ketoglutarate, a compound studied for possible effects on healthy aging, produced opposing lung-tumor responses in female and male mice, according to research highlighted by UCLA Health on September 25. The findings complicate the idea that a metabolic intervention with favorable results in aging experiments will necessarily help in other biological settings.

The study appeared online in Cell Reports on September 23. Its principal evidence comes from experimental cancer models, supported by laboratory and observational human analyses. It does not establish that the supplement prevents cancer in women or increases cancer risk in men.

What the experiments measured

Researchers compared supplemented and control diets over 16 weeks in mice engineered to develop lung adenocarcinoma driven by a KRAS mutation. They assessed tumor growth and cellular characteristics rather than human disease prevention or longevity.

Female mice receiving calcium alpha-ketoglutarate had smaller tumors and less tumor-cell proliferation. Male mice showed larger tumors and more proliferation. Tumor numbers did not change significantly in either sex, suggesting an effect on growth rather than the formation of tumors.

The response also depended on genetics. Removing the tumor-suppressor gene TP53 eliminated the significant tumor-growth reduction seen in the female model. In a different mouse genetic background, the increased tumor burden in males did not recur. Those qualifications make a simple female-benefit, male-harm interpretation unreliable even across mice.

A connection between metabolism and gene regulation

Alpha-ketoglutarate participates in cellular metabolism and supports enzymes involved in regulating chromatin, the material that packages DNA. The researchers examined whether changes in gene regulation accompanied the tumor responses.

Female tumors showed reductions in two histone modifications associated with gene repression, alongside increased activity of genes linked to muscle development. The transcription factor TBX5 also increased. Male tumors showed an increase in one of the repressive histone marks, consistent with a different epigenetic response.

These observations offer a possible explanation for the divergent results. They do not yet establish a complete causal chain explaining why the same intervention behaved differently across sex and genetic background.

The human component adds context without supplying treatment evidence. In lung-adenocarcinoma data, TBX5 expression was higher in female tumors and associated with better survival. An association between a tumor marker and outcome cannot demonstrate that administering a supplement will reproduce that outcome.

Why the findings matter for healthspan research

Interest in calcium alpha-ketoglutarate predates this cancer study. A separate paper published in Cell Metabolism in September 2020 reported longer lifespan in female mice and improved healthspan measures in both sexes. That research followed aging animals and assessed frailty and survival, addressing different questions from the new tumor experiments.

The two studies therefore should not be treated as interchangeable tests. A favorable result on frailty in an aging model cannot establish safety or effectiveness in a model carrying cancer-driving mutations. Conversely, the current tumor findings do not by themselves invalidate the earlier aging measurements.

The practical contribution is a sharper research agenda: metabolic interventions need evaluation across biological sex, genetic background and disease state. For now, calcium alpha-ketoglutarate remains a subject of investigation in these settings. Neither the mouse tumor findings nor the human gene-expression associations establish a cancer-prevention strategy or a human healthspan benefit.